{"id":"placebo-and-ivig","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Aseptic meningitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVIG contains polyspecific immunoglobulins that can neutralize pathogens, block pathogenic antibodies, and modulate inflammatory immune responses through multiple mechanisms including Fc receptor engagement and complement inhibition. In this phase 3 trial context, IVIG is being evaluated against placebo to determine its therapeutic efficacy in a specific indication, likely an autoimmune or immunodeficiency condition.","oneSentence":"IVIG (intravenous immunoglobulin) provides passive immunization by supplying pooled antibodies from healthy donors to modulate immune function, while placebo serves as the control comparator.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:35.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication under investigation in phase 3 trial (specific indication not provided)"}]},"trialDetails":[{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT06742190","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy","status":"RECRUITING","sponsor":"argenx","startDate":"2024-12-18","conditions":"Multifocal Motor Neuropathy (MMN), MMN","enrollment":115},{"nctId":"NCT05701189","phase":"PHASE2","title":"Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome","status":"WITHDRAWN","sponsor":"Chafic Karam","startDate":"2024-09-10","conditions":"Guillain-Barre Syndrome","enrollment":""},{"nctId":"NCT06920004","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP","status":"RECRUITING","sponsor":"argenx","startDate":"2025-08-22","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":218},{"nctId":"NCT05350774","phase":"PHASE2","title":"Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2023-07-10","conditions":"Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis","enrollment":45},{"nctId":"NCT05832034","phase":"PHASE2, PHASE3","title":"Add-on Intravenous Immunoglobulins in Early Myositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-09-13","conditions":"Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome","enrollment":44},{"nctId":"NCT06305780","phase":"PHASE2","title":"RECOVER-AUTONOMIC Platform Protocol","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Covid19, Long Covid-19","enrollment":381},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT05952804","phase":"PHASE2","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-06-10","conditions":"Hematologic Malignancies","enrollment":150},{"nctId":"NCT04910269","phase":"PHASE3","title":"Outpatient Treatment With Anti-Coronavirus Immunoglobulin","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2021-08-06","conditions":"COVID, SARS-CoV2 Infection, Covid19","enrollment":820},{"nctId":"NCT01917721","phase":"PHASE2","title":"Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hawaii Pacific Health","startDate":"2013-10","conditions":"Kawasaki Disease, Coronary Aneurysm","enrollment":50},{"nctId":"NCT04153422","phase":"PHASE2","title":"IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-15","conditions":"Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy","enrollment":20},{"nctId":"NCT01757418","phase":"PHASE1, PHASE2","title":"Intravenous Gammaglobulin for Sickle Cell Pain Crises","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2008-11","conditions":"Sickle Cell Disease, Pain","enrollment":300},{"nctId":"NCT05645107","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2022-12-26","conditions":"Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia","enrollment":386},{"nctId":"NCT02176863","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome","status":"TERMINATED","sponsor":"Instituto Grifols, S.A.","startDate":"2014-09-23","conditions":"Post-polio Syndrome","enrollment":191},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT04502030","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia (\"PRO-SID\" Study)","status":"COMPLETED","sponsor":"Octapharma","startDate":"2020-10-05","conditions":"Chronic Lymphocytic Leukemia, Hypogammaglobulinemia","enrollment":247},{"nctId":"NCT03700138","phase":"PHASE3","title":"Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-06-19","conditions":"Primary Sjögren's Syndrome Painful Sensory Neuropathies","enrollment":24},{"nctId":"NCT06305793","phase":"PHASE2","title":"RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19","enrollment":200},{"nctId":"NCT04372615","phase":"PHASE2","title":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-03-30","conditions":"Autoimmune Encephalitis, Encephalitis","enrollment":116},{"nctId":"NCT03866577","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients","status":"TERMINATED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2018-12-21","conditions":"Immune Thrombocytopenic Purpura (ITP)","enrollment":50},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT06896253","phase":"PHASE2","title":"Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":"Myocarditis Acute","enrollment":120},{"nctId":"NCT03919773","phase":"PHASE1, PHASE2","title":"IVIG (Gamunex-C) Treatment Study for POTS Subjects","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-10-29","conditions":"Postural Tachycardia Syndrome","enrollment":30},{"nctId":"NCT06534450","phase":"PHASE3","title":"The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dobri Kiprov","startDate":"2022-09-12","conditions":"Aging","enrollment":40},{"nctId":"NCT06068608","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy","status":"UNKNOWN","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2023-09-12","conditions":"Varicella","enrollment":48},{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":"Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies","enrollment":13},{"nctId":"NCT03624946","phase":"PHASE1","title":"Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2018-06-27","conditions":"Zika Virus Infection, Zika Virus Disease","enrollment":30},{"nctId":"NCT00448253","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2007-07","conditions":"Symptoms of Inhalational Anthrax","enrollment":92},{"nctId":"NCT02308982","phase":"PHASE3","title":"Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-01","conditions":"Encephalitis","enrollment":18},{"nctId":"NCT04400058","phase":"PHASE3","title":"Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression","status":"COMPLETED","sponsor":"Octapharma","startDate":"2020-06-01","conditions":"Covid-19","enrollment":207},{"nctId":"NCT06183008","phase":"PHASE4","title":"IVIG in Painful Sensory Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Sorlandet Hospital HF","startDate":"2024-02","conditions":"Sensory Neuropathy, Small Fiber Neuropathy","enrollment":20},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":"Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy","enrollment":20},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT04510428","phase":"PHASE2","title":"OSIG-eye Drops Treatment for Dry Eye Disease","status":"WITHDRAWN","sponsor":"University of Illinois at Chicago","startDate":"2023-05-15","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT00841789","phase":"PHASE2","title":"A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease","status":"COMPLETED","sponsor":"Michael Portman","startDate":"2009-03","conditions":"Mucocutaneous Lymph Node Syndrome, Kawasaki Disease","enrollment":205},{"nctId":"NCT01769027","phase":"PHASE2","title":"Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS","status":"WITHDRAWN","sponsor":"CNS Onlus","startDate":"2013-06","conditions":"Pandas","enrollment":""},{"nctId":"NCT01376778","phase":"PHASE3","title":"A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","status":"COMPLETED","sponsor":"The George Washington University Biostatistics Center","startDate":"2012-04","conditions":"Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection","enrollment":399},{"nctId":"NCT05494619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2022-11-30","conditions":"Guillain-Barré Syndrome","enrollment":""},{"nctId":"NCT04847141","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-04-28","conditions":"COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","enrollment":465},{"nctId":"NCT01300728","phase":"PHASE2","title":"Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Sutter Health","startDate":"2011-01-01","conditions":"Mild Cognitive Impairment","enrollment":52},{"nctId":"NCT04450654","phase":"PHASE2","title":"Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2022-05","conditions":"Immune-Mediated Necrotizing Myopathy","enrollment":""},{"nctId":"NCT04546581","phase":"PHASE3","title":"Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-10-08","conditions":"COVID, COVID-19, SARS-CoV-2","enrollment":593},{"nctId":"NCT02184741","phase":"PHASE3","title":"A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage","status":"COMPLETED","sponsor":"Japan Blood Products Organization","startDate":"2014-06-03","conditions":"Recurrent Miscarriage","enrollment":99},{"nctId":"NCT02728752","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-02-27","conditions":"Dermatomyositis","enrollment":95},{"nctId":"NCT00000720","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":250},{"nctId":"NCT02659891","phase":"PHASE1","title":"IVIg to Treat BK Viremia in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-05","conditions":"Kidney Transplantation, BK Virus, Isoantibodies","enrollment":16},{"nctId":"NCT00949065","phase":"PHASE3","title":"Intravenous Immunoglobulins in Complex-regional Pain Syndrome","status":"WITHDRAWN","sponsor":"University of Giessen","startDate":"2009-08","conditions":"Complex Regional Pain Syndrome Type 1","enrollment":""},{"nctId":"NCT00666263","phase":"PHASE3","title":"Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-08-22","conditions":"Multifocal Motor Neuropathy","enrollment":50},{"nctId":"NCT00818662","phase":"PHASE3","title":"A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-12-19","conditions":"Alzheimer´s Disease","enrollment":390},{"nctId":"NCT01524887","phase":"PHASE3","title":"Phase 3 IGIV, 10% in Alzheimer´s Disease","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2012-01-23","conditions":"Alzheimer´s Disease","enrollment":508},{"nctId":"NCT02899702","phase":"PHASE4","title":"Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-09","conditions":"Staphylococcal Infection, Streptococcal Infection","enrollment":""},{"nctId":"NCT04138485","phase":"PHASE2","title":"Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"WITHDRAWN","sponsor":"CSL Behring","startDate":"2019-12-20","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":""},{"nctId":"NCT03010046","phase":"PHASE1","title":"Single Dose Study of ANX005 in Healthy Volunteers","status":"TERMINATED","sponsor":"Annexon, Inc.","startDate":"2016-12","conditions":"Safety and Tolerability in Healthy Volunteers","enrollment":27},{"nctId":"NCT03992482","phase":"PHASE1, PHASE2","title":"IVIG-eye Drops Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Sandeep Jain, MD","startDate":"2019-05-01","conditions":"Dry Eye","enrollment":27},{"nctId":"NCT01281969","phase":"PHASE3","title":"Intravenous Immunoglobulin for PANDAS","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2011-01","conditions":"Obsessive-Compulsive Disorder, Children, Anxiety Disorder","enrollment":48},{"nctId":"NCT02697292","phase":"PHASE3","title":"IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-02","conditions":"Autoimmune Epilepsy","enrollment":17},{"nctId":"NCT00299988","phase":"PHASE2","title":"Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2006-02","conditions":"Alzheimer's Disease","enrollment":24},{"nctId":"NCT02287467","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01","conditions":"Influenza A, Influenza B","enrollment":329},{"nctId":"NCT04041765","phase":"PHASE3","title":"IgM-Enriched Immunoglobulin for Neonatal Sepsis","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-09","conditions":"Neonatal Sepsis, Early-Onset, Very Low Birth Weight Infant, Inflammation","enrollment":70},{"nctId":"NCT02637700","phase":"PHASE2","title":"Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy","status":"COMPLETED","sponsor":"Academisch Ziekenhuis Maastricht","startDate":"2016-07","conditions":"Small Fiber Neuropathy","enrollment":60},{"nctId":"NCT03749096","phase":"PHASE3","title":"Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2018-12-07","conditions":"Stiff-Person Syndrome","enrollment":""},{"nctId":"NCT01295710","phase":"PHASE3","title":"Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Neovii Biotech","startDate":"2011-10-10","conditions":"GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia","enrollment":260},{"nctId":"NCT01203345","phase":"PHASE2, PHASE3","title":"Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"1988-01","conditions":"Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age","enrollment":2416},{"nctId":"NCT00115778","phase":"PHASE2","title":"Intravenous Immunoglobulin (IVIG) in Lung Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2005-06","conditions":"Hypogammaglobulinemia, Lung Transplantation","enrollment":11},{"nctId":"NCT02473952","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-08","conditions":"Myasthenia Gravis, Generalized","enrollment":62},{"nctId":"NCT02956746","phase":"PHASE1, PHASE2","title":"A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2016-08","conditions":"Human Rabies","enrollment":164},{"nctId":"NCT00892112","phase":"PHASE3","title":"Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2009-11","conditions":"Myocardial Diseases, Parvovirus B19, Human","enrollment":50},{"nctId":"NCT01785056","phase":"NA","title":"IVIG Treatment in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-04","conditions":"Systemic Sclerosis, Diffuse Scleroderma","enrollment":14},{"nctId":"NCT01545076","phase":"PHASE3","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy","enrollment":208},{"nctId":"NCT02788188","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-05-28","conditions":"Middle East Respiratory Syndrome Coronavirus","enrollment":38},{"nctId":"NCT01561755","phase":"PHASE4","title":"A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy","status":"TERMINATED","sponsor":"David M. Simpson","startDate":"2012-02","conditions":"HIV-associated Myelopathy","enrollment":12},{"nctId":"NCT01522235","phase":"PHASE2, PHASE3","title":"Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-02","conditions":"Autoimmune Autonomic Ganglionopathy (AAG)","enrollment":6},{"nctId":"NCT00069316","phase":"PHASE2","title":"Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2003-09-22","conditions":"West Nile Virus","enrollment":2},{"nctId":"NCT03166527","phase":"PHASE3","title":"Panzyga in CIDP Administered at Different Infusion Rates","status":"UNKNOWN","sponsor":"Vera Bril","startDate":"2017-06-01","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":30},{"nctId":"NCT02043379","phase":"NA","title":"Post-bypass Prophylactic IVIG in Infants and Neonates","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-05","conditions":"Hypogammaglobulinemia, Congenital Heart Disease","enrollment":50},{"nctId":"NCT01225276","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP","status":"TERMINATED","sponsor":"Octapharma","startDate":"2011-10","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":2},{"nctId":"NCT00000935","phase":"PHASE3","title":"An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"End-Stage Renal Disease, Kidney Transplantation","enrollment":100},{"nctId":"NCT02372149","phase":"PHASE4","title":"IVIg for Demyelination in Diabetes Mellitus","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2015-02","conditions":"Peripheral Neuropathy, Diabetes Mellitus, Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":25},{"nctId":"NCT00177970","phase":"PHASE4","title":"IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2003-10","conditions":"Clostridium Difficile-associated Diarrhea (CDAD)","enrollment":14},{"nctId":"NCT02008578","phase":"PHASE1","title":"Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-12","conditions":"Influenza","enrollment":31},{"nctId":"NCT00376077","phase":"PHASE3","title":"A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-08","conditions":"Immune Thrombocytopenic Purpura","enrollment":32},{"nctId":"NCT00220779","phase":"PHASE2","title":"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":128},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":117},{"nctId":"NCT00220805","phase":"PHASE2","title":"Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-01","conditions":"Macular Degeneration","enrollment":96},{"nctId":"NCT02559921","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2014-12","conditions":"Rabies","enrollment":300},{"nctId":"NCT00760435","phase":"PHASE3","title":"Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-03","conditions":"Kawasaki Disease","enrollment":196},{"nctId":"NCT00722475","phase":"PHASE3","title":"Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2008-08","conditions":"Secondary Recurrent Miscarriage","enrollment":82},{"nctId":"NCT00335985","phase":"PHASE3","title":"Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)","status":"COMPLETED","sponsor":"Japan Blood Products Organization","startDate":"2006-06","conditions":"Polymyositis, Dermatomyositis","enrollment":26},{"nctId":"NCT00675805","phase":"NA","title":"Preventing Intravenous Immunoglobulin-associated Adverse Reactions","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2008-05","conditions":"Immunoglobulin Therapy","enrollment":42},{"nctId":"NCT01545518","phase":"PHASE2","title":"IVIG Treatment for Refractory Immune-Related Adult Epilepsy","status":"TERMINATED","sponsor":"Emory University","startDate":"2011-11","conditions":"Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder","enrollment":20},{"nctId":"NCT00812565","phase":"PHASE2","title":"Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Octapharma","startDate":"2009-02","conditions":"Alzheimer's Disease","enrollment":58},{"nctId":"NCT01628055","phase":"PHASE1","title":"IVIG in Acute Ischemic Stroke: A Pilot Study","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2013-03","conditions":"Ischemic Stroke","enrollment":""},{"nctId":"NCT01867645","phase":"PHASE1","title":"The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2004-12","conditions":"Polyneuropathies","enrollment":38},{"nctId":"NCT01856205","phase":"PHASE2","title":"Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2009-05","conditions":"Japanese Encephalitis","enrollment":22},{"nctId":"NCT01315496","phase":"PHASE3","title":"GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock","status":"TERMINATED","sponsor":"Green Cross Corporation","startDate":"2009-10","conditions":"Severe Sepsis, Septic Shock","enrollment":214},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240},{"nctId":"NCT00606905","phase":"NA","title":"Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage","status":"COMPLETED","sponsor":"University of Chicago","startDate":"1999-11","conditions":"Miscarriage, Recurrent, Abortion, Habitual","enrollment":82},{"nctId":"NCT00063089","phase":"PHASE1, PHASE2","title":"Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever","status":"COMPLETED","sponsor":"Nabi Biopharmaceuticals","startDate":"2002-09","conditions":"Staphylococcal Infections","enrollment":40},{"nctId":"NCT01537575","phase":"PHASE3","title":"Intravenous Immunoglobulins for Post-Polio Syndrome","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2008-01","conditions":"Post-polio Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo and IVIG","genericName":"Placebo and IVIG","companyName":"The Hospital for Sick Children","companyId":"the-hospital-for-sick-children","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IVIG (intravenous immunoglobulin) provides passive immunization by supplying pooled antibodies from healthy donors to modulate immune function, while placebo serves as the control comparator. Used for Indication under investigation in phase 3 trial (specific indication not provided).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}